Compare Flux Power Holdings Inc (FLUX) vs Heron Therapeutics Inc (HRTX) Price & Performance

FLUX trades at $0.461, down 5.96% today, amid a bearish technical signal and weak earnings. Revenue fell to $42M in 2026 with a net loss of $7M, though the P/S ratio of 0.22 suggests undervaluation. The company rejected an unsolicited acquisition proposal from Solidion Technology in October 2026, adding uncertainty. Analyst consensus remains unanimously bullish with 6 buy ratings, contrasting with negative profitability metrics like a -17.68% net income margin.

The outlook is mixed: strong analyst support and low valuation multiples offer potential upside if execution improves, but persistent losses, declining revenue, and acquisition resistance pose significant risks. Investors should weigh the bullish sentiment against fundamental weaknesses and recent volatility.

HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.

The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.